Taysha Gene Therapies (NASDAQ:TSHA) Insider Sells $892,000.00 in Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction that occurred on Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the sale, the insider directly owned 1,136,410 shares in the company, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Sukumar Nagendran also recently made the following trade(s):

• On Monday, January 26th, Sukumar Nagendran sold 26,918 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.61, for a total value of $124,091.98.
• On Friday, January 23rd, Sukumar Nagendran sold 89,132 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.75, for a total value of $423,377.00.

Taysha Gene Therapies Stock Performance

Shares of TSHA opened at $6.00 on Thursday. The company has a quick ratio of 12.23, a current ratio of 12.23 and a debt-to-equity ratio of 0.20. The business’s 50 day moving average price is $4.56 and its 200-day moving average price is $4.74. Taysha Gene Therapies, Inc. has a 52 week low of $1.13 and a 52 week high of $6.04. The stock has a market cap of $1.72 billion, a P/E ratio of -17.65 and a beta of 1.10.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.03. The business had revenue of $5.49 million during the quarter, compared to the consensus estimate of $1.89 million. Equities research analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TSHA has been the topic of several analyst reports. Truist Financial raised Taysha Gene Therapies to a “strong-buy” rating in a research report on Wednesday, March 25th. Wells Fargo & Company upped their price objective on Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. Wall Street Zen raised Taysha Gene Therapies from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Canaccord Genuity Group upped their price objective on Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, April 6th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Friday, March 27th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Taysha Gene Therapies presently has an average rating of “Buy” and a consensus price target of $11.64.

Institutional Investors Weigh In On Taysha Gene Therapies

Hedge funds and other institutional investors have recently modified their holdings of the stock. Marex Group plc purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth $29,000. E Fund Management Co. Ltd. purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth $31,000. ST Germain D J Co. Inc. increased its stake in shares of Taysha Gene Therapies by 81.8% in the 3rd quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after purchasing an additional 4,333 shares in the last quarter. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in shares of Taysha Gene Therapies in the 3rd quarter worth $40,000. Finally, Tower Research Capital LLC TRC increased its stake in shares of Taysha Gene Therapies by 156.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after purchasing an additional 10,742 shares in the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.